PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC

June 4-8, 2021; Online at https://conferences.asco.org/am
Longer-term results from PACIFIC show sustained OS and PFS benefit—with 5-year OS and PFS rates of 42.9% and 33.1%, respectively—with concurrent CRT followed by 1 year of durvalumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 478 KB
Released: June 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Safety and efficacy analysis of larotrectinib in TRK fusion–positive lung cancer, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 15, 2021

Subgroup analysis of IMower010 trial evaluating adjuvant atezolizumab vs best supportive care in patients with resected stage IB-IIIA NSCLC after adjuvant chemotherapy, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 15, 2021

Downloadable powerpoint slideset on the rationale for and use of immune checkpoint inhibitors for resectable early-stage NSCLC from Clinical Care Options

Justin F. Gainor, MD Released: September 13, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue